RHBDF2 and lung cancer: The same experiment in A549 cells confirmed this result in the lung cancer cell line – compared to iRhom2WT, expressing iRhom2D188N in A549-DKO cells caused a more than two-fold increase in the release of endogenous amphiregulin in the presence of oncogenic KRAS (Fig. 6A,B), indicating that tylotic mutation sensitises iRhom2 to oncogenic signalling.